By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

The only man in his immediate family to be without a cancer diagnosis, one Lynch syndrome patient made the trip to ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

🎥 Video Details 🎥 🌟 About This Video 🌟 Cleveland Clinic released December phase-one results for a preventive breast ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Even after surgery and chemotherapy, some cancers, like pancreatic and colorectal, maintain a foothold in the body and ...

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...